Cargando…

Intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in STZ-diabetic mice

Background: Diabetic kidney disease is the leading cause of end-stage renal disease. Administration of ACE inhibitors or/and SGLT2 inhibitors show renoprotective effects in diabetic and other kidney diseases. The underlying renoprotective mechanisms of SGLT2 inhibition, especially in combination wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kroeger, Hannah, Kessel, Friederike, Sradnick, Jan, Todorov, Vladimir, Gembardt, Florian, Hugo, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511053/
https://www.ncbi.nlm.nih.gov/pubmed/36171965
http://dx.doi.org/10.3389/fphys.2022.982722
_version_ 1784797577735045120
author Kroeger, Hannah
Kessel, Friederike
Sradnick, Jan
Todorov, Vladimir
Gembardt, Florian
Hugo, Christian
author_facet Kroeger, Hannah
Kessel, Friederike
Sradnick, Jan
Todorov, Vladimir
Gembardt, Florian
Hugo, Christian
author_sort Kroeger, Hannah
collection PubMed
description Background: Diabetic kidney disease is the leading cause of end-stage renal disease. Administration of ACE inhibitors or/and SGLT2 inhibitors show renoprotective effects in diabetic and other kidney diseases. The underlying renoprotective mechanisms of SGLT2 inhibition, especially in combination with ACE inhibition, are incompletely understood. We used longitudinal intravital microscopy to directly elucidate glomerular hemodynamics on a single nephron level in response to the ACE inhibitor enalapril or/and the SGLT2 inhibitor empagliflozin. Methods: Five weeks after the induction of diabetes by streptozotocin, male C57BL/6 mice were treated with enalapril, empagliflozin, enalapril/empagliflozin or placebo for 3 days. To identify hemodynamic regulation mechanisms, longitudinal intravital multiphoton microscopy was employed to measure single nephron glomerular filtration rate (snGFR) and afferent/efferent arteriole width. Results: Diabetic mice presented a significant hyperfiltration. Compared to placebo treatment, snGFR was reduced in response to enalapril, empagliflozin, or enalapril/empagliflozin administration under diabetic conditions. While enalapril treatment caused significant dilation of the efferent arteriole (12.55 ± 1.46 µm vs. control 11.92 ± 1.04 µm, p < 0.05), empagliflozin led to a decreased afferent arteriole diameter (11.19 ± 2.55 µm vs. control 12.35 ± 1.32 µm, p < 0.05) in diabetic mice. Unexpectedly under diabetic conditions, the combined treatment with enalapril/empagliflozin had no effects on both afferent and efferent arteriole diameter change. Conclusion: SGLT2 inhibition, besides ACE inhibition, is an essential hemodynamic regulator of glomerular filtration during diabetes mellitus. Nevertheless, additional mechanisms—independent from hemodynamic regulation—are involved in the nephroprotective effects especially of the combination therapy and should be further explored in future studies.
format Online
Article
Text
id pubmed-9511053
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95110532022-09-27 Intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in STZ-diabetic mice Kroeger, Hannah Kessel, Friederike Sradnick, Jan Todorov, Vladimir Gembardt, Florian Hugo, Christian Front Physiol Physiology Background: Diabetic kidney disease is the leading cause of end-stage renal disease. Administration of ACE inhibitors or/and SGLT2 inhibitors show renoprotective effects in diabetic and other kidney diseases. The underlying renoprotective mechanisms of SGLT2 inhibition, especially in combination with ACE inhibition, are incompletely understood. We used longitudinal intravital microscopy to directly elucidate glomerular hemodynamics on a single nephron level in response to the ACE inhibitor enalapril or/and the SGLT2 inhibitor empagliflozin. Methods: Five weeks after the induction of diabetes by streptozotocin, male C57BL/6 mice were treated with enalapril, empagliflozin, enalapril/empagliflozin or placebo for 3 days. To identify hemodynamic regulation mechanisms, longitudinal intravital multiphoton microscopy was employed to measure single nephron glomerular filtration rate (snGFR) and afferent/efferent arteriole width. Results: Diabetic mice presented a significant hyperfiltration. Compared to placebo treatment, snGFR was reduced in response to enalapril, empagliflozin, or enalapril/empagliflozin administration under diabetic conditions. While enalapril treatment caused significant dilation of the efferent arteriole (12.55 ± 1.46 µm vs. control 11.92 ± 1.04 µm, p < 0.05), empagliflozin led to a decreased afferent arteriole diameter (11.19 ± 2.55 µm vs. control 12.35 ± 1.32 µm, p < 0.05) in diabetic mice. Unexpectedly under diabetic conditions, the combined treatment with enalapril/empagliflozin had no effects on both afferent and efferent arteriole diameter change. Conclusion: SGLT2 inhibition, besides ACE inhibition, is an essential hemodynamic regulator of glomerular filtration during diabetes mellitus. Nevertheless, additional mechanisms—independent from hemodynamic regulation—are involved in the nephroprotective effects especially of the combination therapy and should be further explored in future studies. Frontiers Media S.A. 2022-09-12 /pmc/articles/PMC9511053/ /pubmed/36171965 http://dx.doi.org/10.3389/fphys.2022.982722 Text en Copyright © 2022 Kroeger, Kessel, Sradnick, Todorov, Gembardt and Hugo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Kroeger, Hannah
Kessel, Friederike
Sradnick, Jan
Todorov, Vladimir
Gembardt, Florian
Hugo, Christian
Intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in STZ-diabetic mice
title Intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in STZ-diabetic mice
title_full Intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in STZ-diabetic mice
title_fullStr Intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in STZ-diabetic mice
title_full_unstemmed Intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in STZ-diabetic mice
title_short Intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in STZ-diabetic mice
title_sort intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in stz-diabetic mice
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511053/
https://www.ncbi.nlm.nih.gov/pubmed/36171965
http://dx.doi.org/10.3389/fphys.2022.982722
work_keys_str_mv AT kroegerhannah intravitalimagingofhemodynamicglomerulareffectsofenalaprilorandempagliflozininstzdiabeticmice
AT kesselfriederike intravitalimagingofhemodynamicglomerulareffectsofenalaprilorandempagliflozininstzdiabeticmice
AT sradnickjan intravitalimagingofhemodynamicglomerulareffectsofenalaprilorandempagliflozininstzdiabeticmice
AT todorovvladimir intravitalimagingofhemodynamicglomerulareffectsofenalaprilorandempagliflozininstzdiabeticmice
AT gembardtflorian intravitalimagingofhemodynamicglomerulareffectsofenalaprilorandempagliflozininstzdiabeticmice
AT hugochristian intravitalimagingofhemodynamicglomerulareffectsofenalaprilorandempagliflozininstzdiabeticmice